Clinical Trial Update: Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) [Phase 2, Phase 3]

View source ↗

Summary

A nonmyeloablative preparative regimen using Mylotarg (gemtuzumab ozogamicin) was studied in Phase 2/Phase 3 trials for high-risk acute myeloid leukemia, acute …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Mylotarg (gemtuzumab ozogamicin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2, Phase 3 | Status: TERMINATED